United States — Food and Drug Administration & American Society of Clinical Oncology

United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.

American Society of Clinical Oncology: The American Society of Clinical Oncology meeting in Chicago was the venue where the significant findings of the daraxonrasib study were presented to the medical community.

United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) has granted two Fast Track Designations to IBI363, indicating its potential to address unmet medical needs and expedite its development and review process.

American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting is the platform where the updated clinical data for IBI363 was presented, providing a significant forum for disseminating these important findings to the medical and scientific community.

United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) granted Fast Track Designation to golidocitinib in February 2022, accelerating its development pathway in the US.

American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting served as the platform for Dizal Pharmaceutical to present its clinical trial results, providing a credible forum for dissemination.

American Society of Clinical Oncology: The American Society of Clinical Oncology (ASCO) Annual Meeting served as a platform for IMUNON to present the unprecedented overall survival data from its Phase 2 OVATION 2 Study of IMNN-001, bringing significant attention to the therapy.